<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313144</url>
  </required_header>
  <id_info>
    <org_study_id>450501</org_study_id>
    <nct_id>NCT00313144</nct_id>
  </id_info>
  <brief_title>Aralast alpha1-proteinase Inhibitor Surveillance Study</brief_title>
  <official_title>ARALAST alpha1-proteinase Inhibitor (α1-PI) Surveillance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this Phase 4, open label, prospective U.S. surveillance study are
      to evaluate the health outcomes of Alpha 1-Antitrypsin (AAT)-deficient subjects who are
      initiating treatment with ARALAST on patient-related outcomes (PRO), i.e., health-related
      quality of life (HRQoL), healthcare resource utilization (HCRU), and various laboratory
      analyses to evaluate the safety of long-term administration of ARALAST.

      Up to 120 subjects will be enrolled and assessed for HRQoL and HCRU at baseline and every
      6-months thereafter, for 2 years. A subset of subjects will be enrolled into the blood draw
      portion of the study, which will also include assessments of antibodies to ARALAST, and
      chemistry panel. Subjects will be treated according to the prescribing (attending)
      physician's instructions based on the prescribing information given in the ARALAST package
      insert.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated early due to Aralast being phased out of the market.
  </why_stopped>
  <start_date type="Actual">June 9, 2006</start_date>
  <completion_date type="Actual">May 1, 2009</completion_date>
  <primary_completion_date type="Actual">December 1, 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HRQoL 'Physical Functioning (PF)' From Baseline to ≤6 Months</measure>
    <time_frame>Screening to ≤ 6 Months</time_frame>
    <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL 'Role Limitation Due to Physical Health (RP)' From Baseline to ≤6 Months</measure>
    <time_frame>Screening to ≤ 6 Months</time_frame>
    <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL 'Bodily Pain (BP)' From Baseline to ≤6 Months</measure>
    <time_frame>Screening to ≤ 6 Months</time_frame>
    <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL 'General Health (GH)' From Baseline to ≤6 Months</measure>
    <time_frame>Screening to ≤ 6 Months</time_frame>
    <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL 'Vitality (VT)' From Baseline to ≤6 Months</measure>
    <time_frame>Screening to ≤ 6 Months</time_frame>
    <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL 'Social Functioning (SF)' From Baseline to ≤6 Months</measure>
    <time_frame>Screening to ≤ 6 Months</time_frame>
    <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL 'Role Limitation Due to Emotional Problems (RE)' From Baseline to ≤6 Months</measure>
    <time_frame>Screening to ≤ 6 Months</time_frame>
    <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL 'Mental Health (MH)' From Baseline to ≤6 Months</measure>
    <time_frame>Screening to ≤ 6 Months</time_frame>
    <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL 'Physical Component Score (PCS)' From Baseline to ≤6 Months</measure>
    <time_frame>Screening to ≤ 6 Months</time_frame>
    <description>SF-36 scores for baseline (screening) versus the period from baseline to ≤6 Months. The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL 'Mental Component Score (MCS)' From Baseline to ≤6 Months</measure>
    <time_frame>Screening to ≤ 6 Months</time_frame>
    <description>SF-36 scores for baseline (screening) versus the period from baseline to ≤6 Months. The MCS is a summary scale of the dimensions vitality, social functioning, role emotional, and mental health Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL For: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS: Baseline, Baseline to ≤6 Months, and &gt;6 Months to ≤12 Months</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>SF-36 Scores- baseline thru 12 months, where data was available. Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The Data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL for PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS Scores: Baseline, Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, and &gt;12 Months to ≤18 Months</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>SF-36 Scores- baseline thru 12 months, where data was available. Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The Data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HRQoL for PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS Scores: Baseline, Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>SF-36 Scores- baseline thru 24 months, where data was available. Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The Data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU) 'Frequency of Emergency Room (ER) Visits'</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>Number of participants with indicated number of ER visits (0, 1, 2, 3, ≥4 ER visits per participant) during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU) 'Mean Number of Emergency Room (ER) Visits'</measure>
    <time_frame>One year prior to baseline to 24 months post-baseline</time_frame>
    <description>Mean number of ER visits one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU) 'Frequency of Hospitalizations'</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>Number of participants with indicated number of hospitalizations during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU) 'Mean Length of Stay (LOS) in Hospital'</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Mean LOS during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU) 'Number of Participants Taking Antibiotics'</measure>
    <time_frame>One year prior to baseline to 24 months post-baseline</time_frame>
    <description>Number of participants taking antibiotics one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU) 'Number of Antibiotic Courses'</measure>
    <time_frame>One year prior to baseline to 24 months post-baseline</time_frame>
    <description>Number of antibiotic courses (i.e. number of antibiotic prescriptions) one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU) 'Number of Participants Receiving Steroid Pulse Courses'</measure>
    <time_frame>One year prior to baseline to 24 months post-baseline</time_frame>
    <description>Number of participants receiving steroid pulse courses (i.e. number of steroid prescriptions) one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU) 'Number of Steroid Pulse Courses'</measure>
    <time_frame>One year prior to baseline to 24 months post-baseline</time_frame>
    <description>Number of steroid pulse courses (i.e. number of steroid prescriptions) one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Chemistry Parameters: Change From Baseline/Screening</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Summary of changes in hepatic (total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase) parameters from screening/baseline through each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal and Hepatic Chemistry Parameters: Change From Baseline/Screening</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Summary of changes in hepatic (total bilirubin) and renal (Blood urea nitrogen (BUN), creatinine) parameters from screening/baseline through each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARALAST Antibody Titers: Participants With at Least 2-Dilution Step Increases From Screening</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>All IgG and IgM titers at screening were ≤ 4. A 2-dilution step increase was defined as follows:
The titer at each 6-month visit must be ≥ 4 when the screening titer = 0
Each 6-month visit titer / screening titer should be ≥ 4. 6 month window periods are: baseline to ≤6 months, &gt;6 months to ≤12 months, &gt;12 months to ≤18 months, and &gt;18 months to ≤24 months</description>
  </secondary_outcome>
  <enrollment type="Actual">127</enrollment>
  <condition>Alpha1-antitrypsin Deficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARALAST Alpha1-Proteinase Inhibitor</intervention_name>
    <description>Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years of age or older

          -  Diagnosis of AAT deficiency associated emphysema

          -  Active prescription for augmentation therapy with ARALAST

          -  On service with Coram (a speciality pharmacy provider)

          -  Signed and dated informed consent

        Exclusion Criteria:

          -  Clinically significant medical (other than COPD), psychiatric, or cognitive illness
             that, in the opinion of Coram or the sponsor or the investigator, may compromise
             subject safety or compliance (such as end stage renal or hepatic or heart disease, or
             metastatic cancer or any difficulty in communicating over the telephone lines)

          -  Previous treatment with ARALAST (i.e. subjects who had previously received and then
             discontinued ARALAST augmentation therapy and are now restarting ARALAST will be
             excluded from the study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adupa Rao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coram</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adupa Rao, MD</name>
      <address>
        <city>San Marino</city>
        <state>California</state>
        <zip>91108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2006</study_first_submitted>
  <study_first_submitted_qc>April 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <results_first_submitted>March 4, 2011</results_first_submitted>
  <results_first_submitted_qc>August 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2011</results_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a surveillance study conducted by Coram, Inc., in locations throughout the United States, and supervised by Baxter. Enrollment began in June 2006 and the study was terminated early, in December 2008, due to Aralast being phased out of the market.</recruitment_details>
      <pre_assignment_details>127 participants enrolled in the study, of these 126 participated in the health related quality of life (HRQoL) and healthcare resource utilization (HCRU) portion, 61 consented to the blood draw portion, and 66 only consented to the Quality of Life portion</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>Participants were treated with ARALAST according to dose and frequency of infusions recommended by their physician.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinue Aralast ≥4 consecutive doses</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Terminated by sponsor/ homecare provider</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event - transient</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Liver transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insurance (homecare provider) change</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change to different product</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Due to termination of the study</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" lower_limit="21.2" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health Related Quality of Life (HRQoL): Baseline Assessment SF-36 Health Domain Scores (n=126)</title>
          <description>The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary score (PCS)=physical functioning, role-physical, bodily pain, and general health; (2) mental component summary score (MCS)=vitality, social functioning, role-emotional, and mental health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Physical Functioning (PF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.612" spread="11.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitation Due to Physical Health (RP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.281" spread="11.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain (BP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.368" spread="11.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health (GH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.351" spread="10.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (VT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.279" spread="11.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning (SF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.699" spread="14.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitation Due to Emotional Problems (RE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.474" spread="10.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health (MH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.326" spread="11.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score (PCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.150" spread="11.263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score (MCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.340" spread="11.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HRQoL 'Physical Functioning (PF)' From Baseline to ≤6 Months</title>
        <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Screening to ≤ 6 Months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL 'Physical Functioning (PF)' From Baseline to ≤6 Months</title>
          <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.958" spread="11.291"/>
                    <measurement group_id="O2" value="33.129" spread="11.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL 'Role Limitation Due to Physical Health (RP)' From Baseline to ≤6 Months</title>
        <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Screening to ≤ 6 Months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL 'Role Limitation Due to Physical Health (RP)' From Baseline to ≤6 Months</title>
          <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.631" spread="11.819"/>
                    <measurement group_id="O2" value="38.139" spread="11.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL 'Bodily Pain (BP)' From Baseline to ≤6 Months</title>
        <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Screening to ≤ 6 Months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL 'Bodily Pain (BP)' From Baseline to ≤6 Months</title>
          <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.474" spread="10.895"/>
                    <measurement group_id="O2" value="48.950" spread="11.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL 'General Health (GH)' From Baseline to ≤6 Months</title>
        <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Screening to ≤ 6 Months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL 'General Health (GH)' From Baseline to ≤6 Months</title>
          <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.365" spread="10.038"/>
                    <measurement group_id="O2" value="38.737" spread="10.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL 'Vitality (VT)' From Baseline to ≤6 Months</title>
        <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Screening to ≤ 6 Months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL 'Vitality (VT)' From Baseline to ≤6 Months</title>
          <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.578" spread="11.164"/>
                    <measurement group_id="O2" value="45.081" spread="10.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL 'Social Functioning (SF)' From Baseline to ≤6 Months</title>
        <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Screening to ≤ 6 Months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL 'Social Functioning (SF)' From Baseline to ≤6 Months</title>
          <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.340" spread="14.060"/>
                    <measurement group_id="O2" value="45.581" spread="12.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL 'Role Limitation Due to Emotional Problems (RE)' From Baseline to ≤6 Months</title>
        <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Screening to ≤ 6 Months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL 'Role Limitation Due to Emotional Problems (RE)' From Baseline to ≤6 Months</title>
          <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.361" spread="10.972"/>
                    <measurement group_id="O2" value="47.921" spread="10.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL 'Mental Health (MH)' From Baseline to ≤6 Months</title>
        <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Screening to ≤ 6 Months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL 'Mental Health (MH)' From Baseline to ≤6 Months</title>
          <description>Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The data transformation process was based on Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.457" spread="10.711"/>
                    <measurement group_id="O2" value="50.007" spread="9.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL 'Physical Component Score (PCS)' From Baseline to ≤6 Months</title>
        <description>SF-36 scores for baseline (screening) versus the period from baseline to ≤6 Months. The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores.</description>
        <time_frame>Screening to ≤ 6 Months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL 'Physical Component Score (PCS)' From Baseline to ≤6 Months</title>
          <description>SF-36 scores for baseline (screening) versus the period from baseline to ≤6 Months. The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.453" spread="10.957"/>
                    <measurement group_id="O2" value="35.826" spread="10.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL 'Mental Component Score (MCS)' From Baseline to ≤6 Months</title>
        <description>SF-36 scores for baseline (screening) versus the period from baseline to ≤6 Months. The MCS is a summary scale of the dimensions vitality, social functioning, role emotional, and mental health Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores.</description>
        <time_frame>Screening to ≤ 6 Months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL 'Mental Component Score (MCS)' From Baseline to ≤6 Months</title>
          <description>SF-36 scores for baseline (screening) versus the period from baseline to ≤6 Months. The MCS is a summary scale of the dimensions vitality, social functioning, role emotional, and mental health Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤6 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.464" spread="11.713"/>
                    <measurement group_id="O2" value="52.378" spread="10.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL For: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS: Baseline, Baseline to ≤6 Months, and &gt;6 Months to ≤12 Months</title>
        <description>SF-36 Scores- baseline thru 12 months, where data was available. Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The Data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤12 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL For: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS: Baseline, Baseline to ≤6 Months, and &gt;6 Months to ≤12 Months</title>
          <description>SF-36 Scores- baseline thru 12 months, where data was available. Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The Data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤12 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning (PF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.822" spread="11.173"/>
                    <measurement group_id="O2" value="35.632" spread="11.251"/>
                    <measurement group_id="O3" value="34.143" spread="11.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitation Due to Physical Health (RP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.539" spread="11.627"/>
                    <measurement group_id="O2" value="39.484" spread="11.615"/>
                    <measurement group_id="O3" value="38.542" spread="13.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain (BP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.203" spread="11.375"/>
                    <measurement group_id="O2" value="50.227" spread="11.267"/>
                    <measurement group_id="O3" value="47.788" spread="13.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health (GH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.853" spread="10.197"/>
                    <measurement group_id="O2" value="39.990" spread="10.013"/>
                    <measurement group_id="O3" value="40.026" spread="11.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (VT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.646" spread="11.546"/>
                    <measurement group_id="O2" value="45.703" spread="11.516"/>
                    <measurement group_id="O3" value="44.742" spread="11.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning (SF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.683" spread="13.864"/>
                    <measurement group_id="O2" value="47.200" spread="11.799"/>
                    <measurement group_id="O3" value="43.927" spread="14.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitation Due to Emotional Problems (RE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.403" spread="11.214"/>
                    <measurement group_id="O2" value="48.583" spread="10.590"/>
                    <measurement group_id="O3" value="48.942" spread="12.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health (MH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.365" spread="11.040"/>
                    <measurement group_id="O2" value="50.311" spread="8.962"/>
                    <measurement group_id="O3" value="49.488" spread="11.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score (PCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.346" spread="10.906"/>
                    <measurement group_id="O2" value="37.890" spread="10.499"/>
                    <measurement group_id="O3" value="36.272" spread="11.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score (MCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.442" spread="11.896"/>
                    <measurement group_id="O2" value="52.508" spread="10.354"/>
                    <measurement group_id="O3" value="51.854" spread="12.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL for PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS Scores: Baseline, Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, and &gt;12 Months to ≤18 Months</title>
        <description>SF-36 Scores- baseline thru 12 months, where data was available. Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The Data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Baseline to 12 months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤18 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL for PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS Scores: Baseline, Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, and &gt;12 Months to ≤18 Months</title>
          <description>SF-36 Scores- baseline thru 12 months, where data was available. Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The Data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤18 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning (PF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.197" spread="11.375"/>
                    <measurement group_id="O2" value="34.958" spread="11.048"/>
                    <measurement group_id="O3" value="33.301" spread="11.764"/>
                    <measurement group_id="O4" value="33.839" spread="12.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitation Due to Physical Health (RP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.492" spread="12.310"/>
                    <measurement group_id="O2" value="39.033" spread="11.686"/>
                    <measurement group_id="O3" value="37.887" spread="12.964"/>
                    <measurement group_id="O4" value="40.336" spread="12.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain (BP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.525" spread="12.023"/>
                    <measurement group_id="O2" value="50.726" spread="10.942"/>
                    <measurement group_id="O3" value="48.990" spread="13.177"/>
                    <measurement group_id="O4" value="50.537" spread="11.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health (GH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.684" spread="10.164"/>
                    <measurement group_id="O2" value="39.718" spread="9.697"/>
                    <measurement group_id="O3" value="39.475" spread="11.435"/>
                    <measurement group_id="O4" value="39.586" spread="10.848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (VT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.714" spread="11.843"/>
                    <measurement group_id="O2" value="46.245" spread="10.807"/>
                    <measurement group_id="O3" value="45.249" spread="11.002"/>
                    <measurement group_id="O4" value="45.648" spread="10.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning (SF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.825" spread="14.089"/>
                    <measurement group_id="O2" value="47.218" spread="11.665"/>
                    <measurement group_id="O3" value="44.781" spread="14.110"/>
                    <measurement group_id="O4" value="45.013" spread="14.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitation Due to Emotional Problems (RE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.014" spread="11.497"/>
                    <measurement group_id="O2" value="48.187" spread="11.158"/>
                    <measurement group_id="O3" value="48.022" spread="13.331"/>
                    <measurement group_id="O4" value="47.360" spread="11.930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health (MH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.390" spread="11.740"/>
                    <measurement group_id="O2" value="50.187" spread="9.347"/>
                    <measurement group_id="O3" value="49.229" spread="12.562"/>
                    <measurement group_id="O4" value="48.569" spread="11.902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score (PCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.803" spread="11.105"/>
                    <measurement group_id="O2" value="37.655" spread="10.609"/>
                    <measurement group_id="O3" value="36.171" spread="10.848"/>
                    <measurement group_id="O4" value="38.060" spread="11.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score (MCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.885" spread="12.215"/>
                    <measurement group_id="O2" value="52.575" spread="10.846"/>
                    <measurement group_id="O3" value="51.843" spread="13.323"/>
                    <measurement group_id="O4" value="50.814" spread="12.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HRQoL for PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS Scores: Baseline, Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months</title>
        <description>SF-36 Scores- baseline thru 24 months, where data was available. Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The Data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
        <time_frame>Baseline to 24 months</time_frame>
        <population>Participants with baseline and participating during the period from baseline to ≤24 months data for HRQoL</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O5">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL for PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS Scores: Baseline, Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months</title>
          <description>SF-36 Scores- baseline thru 24 months, where data was available. Change in quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores. The Data transformation process was based on: Ware et al. How to Score Version 2 of the SF-36® Health Survey. Lincoln, RI: Quality Metric Incorporated; 2000.</description>
          <population>Participants with baseline and participating during the period from baseline to ≤24 months data for HRQoL</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning (PF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.489" spread="11.174"/>
                    <measurement group_id="O2" value="35.988" spread="10.874"/>
                    <measurement group_id="O3" value="34.585" spread="12.241"/>
                    <measurement group_id="O4" value="35.487" spread="12.782"/>
                    <measurement group_id="O5" value="33.883" spread="12.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitation Due to Physical Health (RP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.092" spread="13.267"/>
                    <measurement group_id="O2" value="42.509" spread="11.390"/>
                    <measurement group_id="O3" value="40.643" spread="13.245"/>
                    <measurement group_id="O4" value="42.276" spread="11.577"/>
                    <measurement group_id="O5" value="41.576" spread="12.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain (BP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.036" spread="13.330"/>
                    <measurement group_id="O2" value="53.988" spread="11.695"/>
                    <measurement group_id="O3" value="52.559" spread="14.045"/>
                    <measurement group_id="O4" value="56.041" spread="10.951"/>
                    <measurement group_id="O5" value="51.674" spread="12.214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health (GH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.452" spread="11.496"/>
                    <measurement group_id="O2" value="40.744" spread="10.222"/>
                    <measurement group_id="O3" value="39.632" spread="11.720"/>
                    <measurement group_id="O4" value="40.245" spread="11.852"/>
                    <measurement group_id="O5" value="38.293" spread="11.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (VT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.036" spread="11.949"/>
                    <measurement group_id="O2" value="48.969" spread="10.116"/>
                    <measurement group_id="O3" value="49.118" spread="10.187"/>
                    <measurement group_id="O4" value="47.036" spread="9.797"/>
                    <measurement group_id="O5" value="47.631" spread="10.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning (SF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.980" spread="16.418"/>
                    <measurement group_id="O2" value="48.538" spread="12.026"/>
                    <measurement group_id="O3" value="44.123" spread="14.361"/>
                    <measurement group_id="O4" value="46.980" spread="13.756"/>
                    <measurement group_id="O5" value="48.019" spread="15.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Limitation Due to Emotional Problems (RE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.215" spread="14.077"/>
                    <measurement group_id="O2" value="49.400" spread="12.002"/>
                    <measurement group_id="O3" value="49.770" spread="12.984"/>
                    <measurement group_id="O4" value="49.770" spread="12.142"/>
                    <measurement group_id="O5" value="49.030" spread="12.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health (MH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.801" spread="13.404"/>
                    <measurement group_id="O2" value="50.007" spread="10.686"/>
                    <measurement group_id="O3" value="50.812" spread="13.626"/>
                    <measurement group_id="O4" value="49.471" spread="12.581"/>
                    <measurement group_id="O5" value="50.276" spread="13.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score (PCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.963" spread="11.722"/>
                    <measurement group_id="O2" value="40.480" spread="11.113"/>
                    <measurement group_id="O3" value="38.287" spread="12.037"/>
                    <measurement group_id="O4" value="40.716" spread="10.711"/>
                    <measurement group_id="O5" value="37.890" spread="12.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score (MCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.510" spread="14.484"/>
                    <measurement group_id="O2" value="53.011" spread="12.441"/>
                    <measurement group_id="O3" value="53.120" spread="13.910"/>
                    <measurement group_id="O4" value="51.990" spread="12.726"/>
                    <measurement group_id="O5" value="53.389" spread="15.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU) 'Frequency of Emergency Room (ER) Visits'</title>
        <description>Number of participants with indicated number of ER visits (0, 1, 2, 3, ≥4 ER visits per participant) during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
        <time_frame>Baseline to 24 Months</time_frame>
        <population>Participants with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O2">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU) 'Frequency of Emergency Room (ER) Visits'</title>
          <description>Number of participants with indicated number of ER visits (0, 1, 2, 3, ≥4 ER visits per participant) during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
          <population>Participants with data available during each window period</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 ER visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 ER visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 ER visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 ER visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥4 ER visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU) 'Mean Number of Emergency Room (ER) Visits'</title>
        <description>Mean number of ER visits one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
        <time_frame>One year prior to baseline to 24 months post-baseline</time_frame>
        <population>Participants with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Year Prior to Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O5">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU) 'Mean Number of Emergency Room (ER) Visits'</title>
          <description>Mean number of ER visits one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
          <population>Participants with data available during each window period</population>
          <units>ER visits per time period</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="1.492"/>
                    <measurement group_id="O2" value="0.274" spread="0.594"/>
                    <measurement group_id="O3" value="0.28" spread="0.516"/>
                    <measurement group_id="O4" value="0.15" spread="0.416"/>
                    <measurement group_id="O5" value="0.10" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU) 'Frequency of Hospitalizations'</title>
        <description>Number of participants with indicated number of hospitalizations during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
        <time_frame>Baseline to 24 Months</time_frame>
        <population>Participants with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O2">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU) 'Frequency of Hospitalizations'</title>
          <description>Number of participants with indicated number of hospitalizations during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
          <population>Participants with data available during each window period</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥4 Hospitalizations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU) 'Mean Length of Stay (LOS) in Hospital'</title>
        <description>Mean LOS during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
        <time_frame>Baseline to 24 months</time_frame>
        <population>Participants with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O2">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU) 'Mean Length of Stay (LOS) in Hospital'</title>
          <description>Mean LOS during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
          <population>Participants with data available during each window period</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8585" spread="2.29467"/>
                    <measurement group_id="O2" value="0.6462" spread="2.68346"/>
                    <measurement group_id="O3" value="0.25532" spread="1.374742"/>
                    <measurement group_id="O4" value="1.1905" spread="5.45545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU) 'Number of Participants Taking Antibiotics'</title>
        <description>Number of participants taking antibiotics one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
        <time_frame>One year prior to baseline to 24 months post-baseline</time_frame>
        <population>Participants with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Year Prior to Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O5">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU) 'Number of Participants Taking Antibiotics'</title>
          <description>Number of participants taking antibiotics one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
          <population>Participants with data available during each window period</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU) 'Number of Antibiotic Courses'</title>
        <description>Number of antibiotic courses (i.e. number of antibiotic prescriptions) one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
        <time_frame>One year prior to baseline to 24 months post-baseline</time_frame>
        <population>Participants with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Year Prior to Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O5">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU) 'Number of Antibiotic Courses'</title>
          <description>Number of antibiotic courses (i.e. number of antibiotic prescriptions) one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
          <population>Participants with data available during each window period</population>
          <units>Antibiotic courses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All antibiotic courses (oral and I.V.)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3095" spread="2.84384"/>
                    <measurement group_id="O2" value="0.9906" spread="1.27612"/>
                    <measurement group_id="O3" value="0.9231" spread="1.07975"/>
                    <measurement group_id="O4" value="0.9787" spread="1.40634"/>
                    <measurement group_id="O5" value="0.7143" spread="1.18924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral antibiotic courses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8571" spread="2.39571"/>
                    <measurement group_id="O2" value="0.8679" spread="1.08738"/>
                    <measurement group_id="O3" value="0.8154" spread="0.96651"/>
                    <measurement group_id="O4" value="0.8936" spread="1.25515"/>
                    <measurement group_id="O5" value="0.6667" spread="1.19722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I.V. antibiotic courses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4603" spread="1.08555"/>
                    <measurement group_id="O2" value="0.1038" spread="0.36330"/>
                    <measurement group_id="O3" value="0.1077" spread="0.35895"/>
                    <measurement group_id="O4" value="0.0851" spread="0.28206"/>
                    <measurement group_id="O5" value="0.0476" spread="0.21822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU) 'Number of Participants Receiving Steroid Pulse Courses'</title>
        <description>Number of participants receiving steroid pulse courses (i.e. number of steroid prescriptions) one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
        <time_frame>One year prior to baseline to 24 months post-baseline</time_frame>
        <population>Participants with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Year Prior to Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O5">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU) 'Number of Participants Receiving Steroid Pulse Courses'</title>
          <description>Number of participants receiving steroid pulse courses (i.e. number of steroid prescriptions) one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
          <population>Participants with data available during each window period</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU) 'Number of Steroid Pulse Courses'</title>
        <description>Number of steroid pulse courses (i.e. number of steroid prescriptions) one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
        <time_frame>One year prior to baseline to 24 months post-baseline</time_frame>
        <population>Participants with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Year Prior to Baseline</title>
          </group>
          <group group_id="O2">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O5">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU) 'Number of Steroid Pulse Courses'</title>
          <description>Number of steroid pulse courses (i.e. number of steroid prescriptions) one year prior to baseline/screening, and during each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
          <population>Participants with data available during each window period</population>
          <units>Steroid Pulse Courses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All steroid pulse courses (oral and I.V.)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4365" spread="2.51554"/>
                    <measurement group_id="O2" value="0.4340" spread="0.89463"/>
                    <measurement group_id="O3" value="0.4154" spread="1.07372"/>
                    <measurement group_id="O4" value="0.3404" spread="0.66844"/>
                    <measurement group_id="O5" value="0.2857" spread="0.71714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral steroid pulse courses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0873" spread="2.13174"/>
                    <measurement group_id="O2" value="0.3585" spread="0.84164"/>
                    <measurement group_id="O3" value="0.3692" spread="1.03937"/>
                    <measurement group_id="O4" value="0.2766" spread="0.53981"/>
                    <measurement group_id="O5" value="0.2381" spread="0.70034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I.V. steroid pulse courses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3492" spread="0.96596"/>
                    <measurement group_id="O2" value="0.0849" spread="0.28007"/>
                    <measurement group_id="O3" value="0.0462" spread="0.21145"/>
                    <measurement group_id="O4" value="0.0638" spread="0.24709"/>
                    <measurement group_id="O5" value="0.0476" spread="0.21822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Chemistry Parameters: Change From Baseline/Screening</title>
        <description>Summary of changes in hepatic (total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase) parameters from screening/baseline through each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
        <time_frame>Baseline to 24 months</time_frame>
        <population>Subjects who participated in the blood draws with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O2">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Chemistry Parameters: Change From Baseline/Screening</title>
          <description>Summary of changes in hepatic (total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase) parameters from screening/baseline through each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
          <population>Subjects who participated in the blood draws with data available during each window period</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-39.0" upper_limit="33.0"/>
                    <measurement group_id="O2" value="1.50" lower_limit="-68.0" upper_limit="35.0"/>
                    <measurement group_id="O3" value="-5.50" lower_limit="-70.0" upper_limit="21.0"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-61.0" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-21.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="2.50" lower_limit="-19.0" upper_limit="26.0"/>
                    <measurement group_id="O3" value="2.00" lower_limit="-21.0" upper_limit="35.0"/>
                    <measurement group_id="O4" value="2.00" lower_limit="-27.0" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-25.0" upper_limit="22.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-23.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="1.00" lower_limit="-17.0" upper_limit="27.0"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-10.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal and Hepatic Chemistry Parameters: Change From Baseline/Screening</title>
        <description>Summary of changes in hepatic (total bilirubin) and renal (Blood urea nitrogen (BUN), creatinine) parameters from screening/baseline through each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
        <time_frame>Baseline to 24 months</time_frame>
        <population>Subjects who participated in the blood draws with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O2">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Renal and Hepatic Chemistry Parameters: Change From Baseline/Screening</title>
          <description>Summary of changes in hepatic (total bilirubin) and renal (Blood urea nitrogen (BUN), creatinine) parameters from screening/baseline through each window period (Baseline to ≤6 Months, &gt;6 Months to ≤12 Months, &gt;12 Months to ≤18 Months, and &gt;18 Months to ≤24 Months)</description>
          <population>Subjects who participated in the blood draws with data available during each window period</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-0.2" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.1" upper_limit="0.3"/>
                    <measurement group_id="O3" value="0.04" lower_limit="-0.2" upper_limit="0.2"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-0.2" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.7" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.5" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-0.3" upper_limit="0.6"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-0.5" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="-7.7" upper_limit="9.8"/>
                    <measurement group_id="O2" value="-0.15" lower_limit="-9.2" upper_limit="10.7"/>
                    <measurement group_id="O3" value="1.50" lower_limit="-8.4" upper_limit="7.7"/>
                    <measurement group_id="O4" value="-0.50" lower_limit="-4.3" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ARALAST Antibody Titers: Participants With at Least 2-Dilution Step Increases From Screening</title>
        <description>All IgG and IgM titers at screening were ≤ 4. A 2-dilution step increase was defined as follows:
The titer at each 6-month visit must be ≥ 4 when the screening titer = 0
Each 6-month visit titer / screening titer should be ≥ 4. 6 month window periods are: baseline to ≤6 months, &gt;6 months to ≤12 months, &gt;12 months to ≤18 months, and &gt;18 months to ≤24 months</description>
        <time_frame>Baseline to 24 Months</time_frame>
        <population>Subjects who participated in the blood draws with data available during each window period</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline to ≤6 Months</title>
          </group>
          <group group_id="O2">
            <title>&gt;6 Months to ≤12 Months</title>
          </group>
          <group group_id="O3">
            <title>&gt;12 Months to ≤18 Months</title>
          </group>
          <group group_id="O4">
            <title>&gt;18 Months to ≤24 Months</title>
          </group>
        </group_list>
        <measure>
          <title>ARALAST Antibody Titers: Participants With at Least 2-Dilution Step Increases From Screening</title>
          <description>All IgG and IgM titers at screening were ≤ 4. A 2-dilution step increase was defined as follows:
The titer at each 6-month visit must be ≥ 4 when the screening titer = 0
Each 6-month visit titer / screening titer should be ≥ 4. 6 month window periods are: baseline to ≤6 months, &gt;6 months to ≤12 months, &gt;12 months to ≤18 months, and &gt;18 months to ≤24 months</description>
          <population>Subjects who participated in the blood draws with data available during each window period</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire study period (2 years, 7 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colon gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="7" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="123" subjects_affected="15" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="28" subjects_affected="13" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="27" subjects_affected="7" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="35" subjects_affected="24" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="66" subjects_affected="33" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="45" subjects_affected="28" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="98" subjects_affected="23" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="33" subjects_affected="23" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Elective procedure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Poor venous access</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter's agreements with PIs vary per individual PI, but contain common elements. Baxter may require a review of results communications (e.g., for confidential information &amp; intellectual property) ≥45 days prior to submission or communication for review and comment. Baxter reserves the right to remove all confidential information from all publications.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to Aralast being phased out of the market.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Gelmont, MD Global Medical Director, Head of Specialty Products TA, BioTherapeutics</name_or_title>
      <organization>Baxter Healthcare Corporation</organization>
      <email>david_gelmont@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

